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DObjective:Most studies describing the outcome of coronary artery bypass grafting patients supported preoper-
atively with an intra-aortic balloon pump (IABP) have reported early results. The purpose of our study was to
evaluate the early and long-term results.
Methods: Of 2658 isolated coronary artery bypass grafting procedures performed from 1996 to 2001, 215 were
supported preoperatively with an IABP. The indications for IABP insertion were cardiogenic shock in 18
(8.4%), acute evolving myocardial infarction in 38 (17.7%), clinical instability in 84 (39.1%), and critical cor-
onary lesions in 75 (34.9%).
Results: Operative mortality was 12.6%. The mortality of the cardiogenic shock patients was greater (22.2%;
P ¼ .174). Logistic regression analysis showed patient age (odds ratio, 1.057; 95% confidence interval,
1.010-1.108) and cardiopulmonary bypass (CPB) time (odds ratio, 1.020; 95% confidence interval,
1.008-1.031) were associated with increased operative mortality. An increased number of bypass grafts had a
protective effect (odds ratio, 0.241; 95% confidence interval, 0.113-0.515). The actual early mortality was lower
than the logistic EuroSCORE calculated mortality (12.6% vs 32.8%, P<.0001). The mean follow-up was 8 4
years. The Kaplan-Meier 10-year survival was 49%. The Cox adjusted overall (early and late) survival and ma-
jor adverse cardiac events-free survival of the different IABP subgroups was similar. Cox analyses showed pe-
ripheral vascular disease, off-pump coronary artery bypass surgery, age, CPB time, female gender, and fewer
bypass grafts were associated with decreased survival.
Conclusions: In patients supported preoperatively with an IABP, better early and long-term results were
strongly related to younger age, a shorter CPB time, and a greater number of bypass grafts. Avoiding the use
of CPB (off pump) in these emergency cases is not recommended. (J Thorac Cardiovasc Surg 2014;148:1869-75)Several clinical studies have demonstrated improved
outcome with insertion of an intra-aortic balloon pump
(IABP) before surgery.1,2 However, other clinical studies
have failed to detect a significant difference in outcomes
with the use of a preoperative IABP.3,4 The greater rates
of IABP-related complications observed in the past have
dissuaded some surgeons from routine preoperative use of
IABP in high-risk patients.4
The introduction of new IABP guidewires and technolog-
ical improvements in catheter size and software have
reduced the occurrence of complications5 and have
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The Journal of Thoracic and CarMost studies describing the outcome of high-risk coro-
nary patients who have undergone surgery with preopera-
tive IABP support have reported early results. The
purpose of our study was to evaluate the early and long-
term (15 years postoperatively) results.METHODS
Of 2658 patients undergoing isolated coronary artery bypass grafting
(CABG) at Tel Aviv Medical Center from 1996 to 2001, 215 (8.1%)
were supported preoperatively with an IABP that was not removed before
surgery. The preoperative and intraoperative patient data (Table 1) and the
indication for IABP insertion were collected from the hospital medical re-
cords. The indications for IABP insertion were cardiogenic shock (sub-
group 1) in 18 (8.4%), acute evolving myocardial infarction (MI) with
critical coronary stenosis (subgroup 2) in 38 (17.7%), clinical instability
(subgroup 3) in 84 (39.1%), and critical coronary lesions without evidence
of MI (subgroup 4) in 75 (34.9%). The expected operative mortality was
calculated using the logistic EuroSCORE.7 Follow-up data were obtained
after institutional review board approval using a telephone questionnaire
and the Israeli National Registry database.
Surgical Techniques
The IABP was inserted in all patients preoperatively, in most, in the
catheterization laboratory.
Surgery was performed with standard cardiopulmonary bypass (CPB)
or off-pump coronary artery bypass (OPCAB). Myocardial preservation
during CPB involved intermittent, antegrade, or antegrade plus retrogradediovascular Surgery c Volume 148, Number 5 1869
Abbreviations and Acronyms
BITA ¼ bilateral internal thoracic artery
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
IABP ¼ intra-aortic balloon pump
ITA ¼ internal thoracic artery
MACE ¼ major adverse cardiac events
MACCE¼major adverse cardiac or cerebrovascular
events
MI ¼ myocardial infarction
OPCAB ¼ off-pump coronary artery bypass
OR ¼ odds ratio
PVD ¼ peripheral vascular disease
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Dblood cardioplegia (30-32C). Coronary stabilization during OPCAB was
facilitated with CTS stabilizers (Guidant, Cupertino, Calif) or the Octopus
system (Medtronic, Minneapolis, Minn). Internal thoracic arteries (ITAs)
were mobilized from the chest wall as skeletonized vessels. During the
study period, in all patients undergoing bilateral ITA (BITA) grafting, BI-
TAs were used to graft the left coronary system (ie, the myocardial territory
supplied by the left anterior descending and left circumflex arteries).8
The department’s strategy was to use the right ITAs, right gastroepiploic
arteries, and radial arteries as grafts to the right coronary artery branches
only in the presence of significant stenosis (ie,>80%).9,10 However, in
most cases, a saphenous vein graft was the preferred conduit for right
coronary artery revascularization. The surgical variables are summarized
in Table 2.
To decrease the risk of spasm of the arterial grafts, we treated all our pa-
tients with a high-dose intravenous infusion of isosorbide dinitrate (Isoket,
See Agis, Monheim, Germany) during the first 48 hours postoperatively.
Calcium channel blockers (diltiazem 90 to 180 mg/d orally) were given
to patients operated on using the right gastroepiploic artery or radial artery
from the second postoperative day for 3 months.8
Definition of Terms and Data Collection
The patient data were analyzed according to the American College of
Cardiology/American Heart Association clinical data standards.11
A perioperative MI was defined by the appearance of new Q waves on
the electrocardiogram associated with elevated levels of creatine
phosphokinase-MB fraction >50 mU/mL. A cerebrovascular accident
was defined as a new permanent neurologic deficit and computed tomogra-
phy evidence of cerebral infarction. Chronic renal failure was diagnosed if
the creatinine level was>1.8 mg/dL. Our definition of an ‘‘emergency
operation’’ was determined using the Society of Thoracic Surgeons guide-
lines12 and included patients operated on within 24 hours of cardiac cath-
eterization, with ongoing angina, failed percutaneous transluminal
coronary angioplasty, acute evolving MI, pulmonary edema, and cardio-
genic shock. For patients who needed emergency surgery and were not sta-
bilized after intra-aortic balloon counterpulsation, we usually used 1 ITA
combined with saphenous vein grafts. Deep sternal infection was defined
as the sum of deep infection and late dehiscence requiring sternectomy.
An IABP-related vascular complication was defined as an acute perfusion
compromise to a limb or an organ distal to the balloon position. An early
unfavorable event was defined as the occurrence in the perioperative period
of either 1 of the following: acute MI, acute cerebral infarct, deep sternal
infection, IABP-related vascular complications, need for revision, or death.
Major adverse cardiac events (MACE) were defined as the occurrence
of cardiac-related mortality, nonfatal MI, or the need for repeat coronary1870 The Journal of Thoracic and Cardiovascular Surrevascularization. Major adverse cardiac or cerebrovascular events
(MACCE) were defined as either MACE or cerebral infarct. Complete
revascularization was defined as revascularization of all coronary systems
with vessel stenosis>70%.
Statistical Analysis
Data are expressed as the mean  standard deviation or as a propor-
tion. The chi-square test and 2-sample t test was used to compare
discrete and continuous variables, respectively. Multivariate logistic
regression analysis was used to predict early mortality and early unfa-
vorable events using various risk factors. The odds ratios (ORs) and
95% confidence intervals (CIs) are presented. The Cox proportional
hazards model was used to evaluate the influence of perioperative and
operative variables on overall (early plus late) mortality and morbidity
(MACE, MACCE, and angina recurrence). We used the stepwise condi-
tional forward selection method in all multivariate analyses; however,
the IABP subgroups were forced into all models. The results of the
Cox analysis are expressed as hazard ratios and 95% CIs. Postoperative
survival is expressed using the Kaplan-Meier method, and the survival
curves were compared using the log-rank test. The Cox model was
used for coronary risk-adjusted curves. All analyses were performed
with Statistical Package for Social Sciences, version 18, software
(SPSS, Inc, Chicago, Ill).RESULTS
The patients’ preoperative and operative characteristics
are listed in Tables 1 and 2. The mean number of grafts
per patient was 2.67. Of the patients, 53 (24.6%)
underwent surgery without CPB (OPCAB). The average
CPB time for patients treated with CPB was 94.5  39
minutes, and the mean aortic crossclamp time was 72.0 
25 minutes. Operative mortality (30 days postoperatively)
in the cohort of 215 consecutive IABP-supported patients
was 12.6%. The early mortality of the patients with cardio-
genic shock was 22.2% (4 of 18; P ¼ .174 compared with
the other subgroups of IABP insertion indications). Opera-
tive mortality for the female patients was 19.7% (12 of 61;
P ¼ .043) and for the patients with acute evolving MI was
17.1% (18 of 105; P ¼ .037; Table 3).
Multivariate logistic regression analysis revealed that
operative mortality was related to CPB time (P ¼ .001;
OR, 1.020; 95% CI, 1.008-1.031) and patient age
(P ¼ .018; OR, 1.057; 95% CI, 1.010-1.108). A CPB
time of 70 minutes was a good threshold at which to best
separate patients with good and poor outcomes. The mortal-
ity of patients with a CPB time of 70 minutes was 6.5%
versus 14% and 17% for a longer CPB time and OPCAB,
respectively (P<.001).
The use of BITAs was associated with decreased early
mortality, as expected for the BITA patients (5.8% vs
17.1% for non-BITA patients; P ¼ .011). However, BITA
did not emerge as a significant predictor on multivariate
analysis. An increased number of bypass grafts had a pro-
tective effect (OR, 0.241; 95% CI, 0.113-0.515; P<.001).
Themean additive and logistic EuroSCORE for the entire
cohort was 12 3 and 32 2, respectively. The actual early
postoperative mortality observed in each of the IABPgery c November 2014
TABLE 1. Patient characteristics and overall (early and late) crude
mortality*
Factor Prevalencey
Mortality
with factor
Mortality
without factor
P
value
Cardiogenic shock 18 (7.9) 14 (77.8) 106 (53.8) .026
Female gender 61 (28.4) 47 (78.3) 73 (49.3) <.001
Age — 72.1  9.5 63.9  11.1 <.001
EuroSCORE — 13.5  3 10.5  2.3 <.001
Age  70 y 106 (49.3) 74 (69.8) 46 (45.1) <.001
NIDDN 53 (27.5) 34 (64.2) 86 (55.5) NS
IDDM 8 (3.7) 6 (75) 114 (57) NS
Hypertension 138 (64.2) 90 (65.2) 30 (42.9) .002
COPD 23 (10.7) 15 (65.2) 105 (56.8) NS
CHF 32 (14.9) 26 (81.3) 94 (53.4) .002
PVD 42 (19.5) 37 (88.1) 83 (50) <.001
CRF 19 (8.8) 16 (84.2) 104 (55) .011
Functional
neurologic
dysfunction
10 (4.7) 10 (100) 110 (55.6) .003
UAP 181 (84.2) 104 (57.5) 16 (59.3) NS
Old MI (30 d) 61 (28.4) 44 (72.1) 76 (51.7) .005
Acute MI (<1 wk) 105 (48.8) 64 (62.9) 56 (52.9) NS
EF  35% 40 (18.6) 27 (67.5) 93 (55.4) NS
Left main stenosis 120 (55.8) 65 (54.2) 55 (62.5) NS
Previous PCI 42 (19.5) 33 (78.6) 87 (52.4) .002
3-Vessel disease
(vs 2-vessel
disease)
145 (67.4) 90 (62.1) 30 (47.6) .037
Data presented as n (%) or mean  standard deviation. NIDDM, Noninsulin-
dependent diabetes mellitus; NS, not significant; IDDM, insulin-dependent diabetes
mellitus; COPD, chronic obstructive pulmonary disease; CHF, congestive heart fail-
ure; PVD, peripheral vascular disease; CRF, chronic renal failure; UAP, unstable
angina pectoris; MI, myocardial infarction; EF, ejection fraction; PCI, percutaneous
coronary intervention. *Number of deaths/number of patients in the subgroup with
long-term follow-up data. yNumber of patients in the subgroup/215 patients.
TABLE 3. IABP and early mortality
Factor Prevalence*
Mortality
with factor
Mortality
without factor P value
Female gender 61 (28.4) 12 (19.7) 15 (9.7) .043
Acute MI 105 (48.8) 18 (17) 9 (8.2) .037
Recent MI 113 (52.6) 19 (16.8) 8 (7.8) .037
BITA 86 (40.0) 5 (5.8) 22 (17.1) .011
Single bypass 29 (13.5) 10 (34.5) 17 (9.1) .001
Cardiogenic
shock
18 (8.4) 4 (22.2) 23 (11.7) NS
Subgroup 2 38 (17.7) 6.15 (8) 21 (11.9) NS
Subgroup 3 84 (39.1) 14 (16.7) 13 (10.9) NS
Subgroup 4 75 (34.9) 3 (4) 24 (17.1) NS
Age  70 y 106 (49.3) 15 (14.1) 12 (11) NS
NIDDM 53 (27.5) 4 (7.5) 23 (14) NS
IDDM 8 (3.7) 1 (12.5) 26 (12.5) NS
Hypertension 138 (64.2) 16 (11.5) 11 (14.3) NS
COPD 23 (10.7) 4 (17.4) 23 (12) NS
CHF 32 (14.9) 5 (15.6) 22 (12) NS
PVD 42 (19.5) 6 (14.2) 21 (12.1) NS
CRF 19 (8.8) 4 (21) 23 (11.7) NS
Neurologic
dysfunction
10 (4.7) 1 (10) 26 (12.7) NS
Old MI 61 (28.4) 8 (13.1) 19 (9.1) NS
EF  35% 40 (18.6) 8 (20) 19 (10.8) NS
Left main artery 120 (55.8) 12 (10) 15 (15.8) NS
Previous PCI 42 (19.5) 7 (16) 20 (10.8) NS
3VD vs 2VD 145 (67.4) 17 (1.7) 10 (14.2) NS
Data presented as n (%). IABP, Intra-aortic balloon pump;MI, myocardial infarction;
BITA, bilateral internal thoracic artery; Subgroup 2, evolving MI (24 h); Subgroup 3,
clinical instability; Subgroup 4, critical coronary lesions; NIDDM, noninsulin-
dependent diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; COPD,
chronic obstructive pulmonary disease; CHF, congestive heart failure; PVD, periph-
eral vascular disease; CRF, chronic renal failure; EF, ejection fraction; PCI, percuta-
neous coronary intervention; VD, vessel disease; NS, not significant. *Number of
patients in the subgroup/215 patients.
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Dindication subgroups and in the entire cohort was lower than
the logistic EuroSCORE calculated mortality (Table 4).
A total of 4 (1.9%) perioperative MIs, 4 (1.9%) sternal
wound infections, 15 (7%) cerebral infarctions, 13 (6%)
IABP-related vascular complications, and 10 (4.7%) revi-
sions occurred. An increased risk (univariate) ofTABLE 2. Patient operative data and overall crude mortality*
Factor Prevalencey
Mortality
with factor
Mortality
without factor
P
value
Repeat operation 15 (7.0) 13 (86.7) 107 (55.4) .015
BITA 86 (40) 36 (42.9) 84 (67.7) <.001
SVG 112 (52.1) 66 (58.9) 54 (56.3) NS
RGEA 6 (2.8) 3 (50) 117 (57.9) NS
Bypass to RCA 114 (53.0) 59 (51.8) 61 (64.9) .038
OPCAB 53 (24.6) 41 (77.4) 79 (51) .001
CPB time (min) — 66.3  60.9 76.6  41.5 NS
Data presented as n (%) or mean  standard deviation. BITA, Bilateral internal
thoracic artery; SVG, saphenous vein graft; NS, not significant; RGEA, right gastro-
epiploic artery; RCA, right coronary artery; OPCAB, off-pump coronary artery
bypass; CPB, cardiopulmonary bypass. *Number of deaths/number of patients in
the subgroup with long-term follow-up data. yNumber of patients in the subgroup/
215 patients.
The Journal of Thoracic and Carperioperative cerebral infarctions was found among pa-
tients 70 years (12 of 106, 11.3%), patients with
insulin-dependent diabetes mellitus (4 of 8, 50%), and pa-
tients with peripheral vascular disease (PVD) (6 of 42,
14.3%). IABP-related vascular complications were more
common among patients with PVD (14.3%), acute MI
(9.5%), and old MI (11.3%).TABLE 4. Observed early mortality and logistic EuroSCORE
expected early mortality
Group
EuroSCORE
expected mortality
Observed
mortality
P
value
Subgroup 1 (n ¼ 18) 8 (43.5) 4 (22.2) .174
Subgroup 2 (n ¼ 38) 12 (32.3) 6 (15.6) .092
Subgroup 3 (n ¼ 84) 33 (38.9) 14 (16.7) .001
Subgroup 4 (n ¼ 75) 18 (23.6) 3 (4.0) .0005
Total (n ¼ 215) 70 (32.8) 27 (12.6) <.00001
Data presented as n (%). Subgroup 1, Cardiogenic shock; Subgroup 2, evolving
myocardial infarction (24 h); Subgroup 3, clinical instability; Subgroup 4, critical cor-
onary lesions.
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FIGURE 1. Survival curves (Kaplan-Meier) of single internal thoracic ar-
tery (ITA) versus bilateral ITA (BITA) grafting.
FIGURE 3. Relation between long-term Cox-adjusted survival and the
number of bypass grafts performed.
TABLE 5. Cox proportional hazards model for total mortality and
long-term morbidity
Variable HR 95% CI P value
Total mortality
PVD 2.508 1.657-3.794 <.001
OPCAB 3.877 1.962-7.660 <.001
Age 1.040 1.020-1.061 <.001
CPB time 1.012 1.006-1.018 <.001
Bypass graft number 0.650 0.490-0.863 .003
Female gender 1.580 1.054-2.369 .027
Acquired Cardiovascular Disease Hemo et al
A
C
DFollow-up data for 1 to 180 months postoperatively
(mean, 8 4 years) was available for 95.7% of the surviving
patients (180 of 188); 93 late deaths occurred. The 10-year
actuarial survival (Kaplan-Meier) was 48.7%  3.5%.
The 10-year survival of female patients was 31.7%  6%
compared with 58.3%  6% for the male patients
(P<.001, log-rank test). The 10-year survival of patients
with PVD was 21.4%  6.3% compared with 58.8% 
6.8% for those without PVD (P < .001), that of the
OPCAB patients (23.6%  6% vs 67.4%  7.2%; P<
.001 CPB patients), and that of the cardiogenic shock sub-
group was 35.3% 11.6%. The survival of the cardiogenic
shock subgroup was significantly lower than the survival of
the other 3 subgroups (56.6%  8.2%, 42%  5.5%,
55.4%  5.9% for subgroups 2, 3 and 4 respectively;
P¼ .049). The 10-year survival of BITA patients was signif-
icantly better than that of patients treated using a single ITA
(62.6%  5.3% vs 39.5%  4.4%; P<.001; Figure 1).
The relationship between the preoperative and operative
patient characteristics and ‘‘crude’’ overall mortality rate
estimates (ie, the number of dead divided by the total num-
ber of patients in the subgroup) is demonstrated in Tables 1
and 2.FIGURE 2. Cox-adjusted survival of off-pump coronary artery bypass
(OPCAB) versus cardiopulmonary bypass (CPB) patients.
1872 The Journal of Thoracic and Cardiovascular SurThe Cox-adjusted overall (early and late) survival and
MACE- and MACCE-free survival of the different IABP
subgroups were similar.
The Cox analyses showed that PVD, OPCAB (Figure 2),
age, CPB time, and female gender were associated with
increased overall mortality. On the other hand, a greater
number of bypass grafts improved overall survival
(Figure 3 and Table 5).
Diabetes mellitus, repeat operation, OPCAB, and an
increased CPB time were predictors of shorter MACE-
and MACCE-free survival. An additional predictor ofMACE
OPCAB 4.732 1.843-12.154 .001
DM 2.259 1.356-3.763 .002
Repeat operation 3.134 1.470-6.684 .003
CPB time 1.011 1.002-1.019 .011
HTN 1.869 1.056-3.306 .032
MACCE
OPCAB 6.205 2.340-16.453 <.001
DM 2.045 1.277-3.273 .003
PVD 2.073 1.228-3.501 .006
Old MI 1.832 1.165-2.881 .009
CPB time 1.012 1.003-1.020 .010
Repeat operation 2.394 1.142-5.020 .021
HR, Hazard ratio; CI, confidence interval; PVD, peripheral vascular disease; OPCAB,
off-pump coronary artery bypass; CPB, cardiopulmonary bypass; MACE, major
adverse cardiac events; DM, diabetes mellitus; HTN, hypertension; MACCE, major
adverse cardiac or cerebrovascular events; MI, myocardial infarction; PVD, periph-
eral vascular disease.
gery c November 2014
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Dreduced MACE-free survival was hypertension, and addi-
tional predictors of reduced MACCE-free survival were
old MI and PVD (Table 5).
When the logistic EuroSCORE was forced into the Cox
model, it was an independent and a strong predictor of
MACE and MACCE (hazard ratio, 1.022; 95% CI, 1.010-
1.034; P<.001; and hazard ratio, 1.019; 95% CI, 1.007-
1.030; P ¼ .001, respectively).
Angina pectoris returned in 32.4% of the patients stud-
ied. Univariate and multivariate (Cox) analysis did not
show any difference among the IABP subgroups in the
recurrence of angina.
DISCUSSION
In recent years, with the enormous growth of interven-
tional cardiology, many patients have been referred for
CABG at the end stage of their disease, with an ischemic
myocardium and energy-depleted heart. Therefore, short-
term preoperative cardiac circulatory support with an
IABP might be required. Although a consensus exists
regarding IABP use in patients with cardiogenic shock
and unstable conditions after an acute evolving MI, contro-
versy remains regarding the routine use of IABP for other
subgroups of high-risk patients.13 A recently published
meta-analysis of 4 randomized controlled trials and 6 cohort
studies of 1034 patients supported the preoperative use of
IABP in high-risk patients.14 Most studies reporting the re-
sults of preoperative IABP support for CABG patients have
been small, single-center, retrospective reports without
long-term follow-up. The only studies containing larger
numbers of patients have been multicenter studies with a
relatively small number of patients recruited from each cen-
ter,15 only 1 of which described the midterm results.3
The cohort of patients described in the present report
was large (n ¼ 215) and included relatively high-risk pa-
tients (mean additive EuroSCORE, 12  3). All patients
required emergency surgery, and 18 (8.3%) were in
cardiogenic shock preoperatively. The actual early postop-
erative mortality in each of the IABP subgroups and the
entire cohort was lower than the logistic EuroSCORE
calculated mortality (12.6% and 32.8%, respectively).
The operative mortality in the cardiogenic shock subgroup
was lower than that described in the Cardiogenic Shock
trial.16 It was about one half of the EuroSCORE expected
mortality (22.2% vs 43.5%). Older age, a prolonged CPB
time, and fewer bypass grafts were associated with an
increased risk of operative mortality (multivariate logistic
regression analysis). In contrast to the cited series that
concentrated on early postoperative results, our series
also included detailed long-term (15 years) postoperative
follow-up data.
An important finding of our study was that the adjusted
overall (early and late) survival and MACE- and
MACCE-free survival of the different IABP subgroupsThe Journal of Thoracic and Car(including the cardiogenic shock and acute MI subgroups)
was similar. Cox analyses showed that PVD, OPCAB,
advanced age, longer CPB time, female gender, and fewer
bypass grafts were associated with decreased survival. OP-
CAB and longer CPB time were predictors of shorter
MACE- and MACCE-free survival.CPB Time
In our experience (including the patients in the present
study), a prolonged CPB time will not relate necessarily
to the number of bypass grafts performed but rather to the
increased time needed to wean from CPB.
Previous studies have reported a prolonged CPB time to
be a risk factor for early and late mortality.17 Our results
support this observation and showed that a prolonged
CPB time was an independent predictor of early and overall
mortality. A prolonged CPB time was also associated with
an increased occurrence of MACE and MACCE.OPCAB Surgery
Displacement of the heart during OPCAB has often been
associated with hemodynamic deterioration, especially
when grafting the marginal branches of the circumflex cor-
onary artery and the left ventricular branch of the right cor-
onary artery, which sometimes barely emerges from the
atrioventricular groove. Elective preoperative insertion of
an IABP has appeared to facilitate intraoperative manage-
ment of these vessels by reducing the hemodynamic insta-
bility associated with positioning of the heart.18
The OPCAB preferred approach was adopted in our cen-
ter in 1999, the middle of the present study period, and was,
therefore, the main indication for OPCAB use in the pa-
tients with IABPs included in our study.
Our study results have negated a previously published
study suggesting better outcomes for high-risk OPCAB pa-
tients who were compared with high-risk on-pump pa-
tients.19 Our study included 53 IABP-supported OPCAB
patients; these patients had significantly greater early mor-
tality than the 162 IABP-supported patients who underwent
CPB. The OPCAB patients in our series had lower actuarial
(Kaplan Meier) 10-year survival (24%  6% vs 57% 
4%; P<.001). Moreover, OPCAB was an independent pre-
dictor of decreased overall (early and late) survival and
decreased MACE- and MACCE-free survival (Cox model).
The decreased long-term patency rates of anastomoses per-
formed on a beating heart and less complete revasculariza-
tion could explain the inferior early and late outcomes of the
OPCAB patients.19,20 The fact that the number of bypass
grafts was included in the Cox model suggests that the
poor outcomes of the OPCAB patients in our report
were independent of the completeness of the
revascularization and the number of grafts performed on
the beating heart.diovascular Surgery c Volume 148, Number 5 1873
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DAge
Multivariate analysis in our study revealed that increased
age was associated with in-hospital and overall (early plus
late) mortality. In addition, the occurrence of early unfavor-
able events (the sum of perioperative MI, cerebral infarct,
deep sternal infection, IABP-related vascular complication,
the need for revision, and death) was greater for patients
70 years old. These findings in the preoperative IABP-
supported patients are in concordance with previously pub-
lished analyses of early and late results after CABG.8 Age is
among the most important factors affecting early mortality
and morbidity in the most recent Society of Thoracic Sur-
geons risk model.12Number of Bypass Grafts
An increased number of bypass grafts in our group of
IABP-supported patients was associated with decreased
in-hospital mortality (multivariate logistic regression anal-
ysis). The patients with fewer grafts also had decreased
adjusted long-term survival (Cox model). The decreased
survival of patients with a lower number of bypass grafts
could have been related to the presence of more diffuse dis-
ease, limiting the number of grafts that could be done. It
could also have been related to incomplete
revascularization.
These results support the well-established idea that
providing complete revascularization during CABG will
improve early and long-term survival. However, our results
negate those of a large-scale, recently published report that
has suggested that in the presence of a left internal mam-
mary artery to left anterior descending artery anastomosis,
reasonable incomplete revascularization of the circumflex
and right coronary artery territories will not adversely affect
early or long-term survival.21 A possible explanation for
this discrepancy might be the difference between the 2
studies in the prevalence of high-risk patients and emer-
gency cases. The achievement of complete revasculariza-
tion in these high-risk patients with energy-depleted
hearts might be more influential on the early and long-
term results; however, long-term survival is also likely
affected by the better patency rate of the BITA grafts used
for grafting in 40% of the patients in our study.22
We recommend the use of BITA grafts for IABP-
supported patients to all surgeons experienced with this
grafting technique. A part of the reason that BITA patients
did better (in addition to selection bias and the benefits
directly related to the conduits) was probably because our
cardiac surgical unit has routinely used BITA grafting for
CABG (ie, facile with the use of BITA grafts in general).Peripheral Vascular Disease
In a large multicenter study of 16,909 IABP-supported
patients, balloon-related complications (major limb1874 The Journal of Thoracic and Cardiovascular Surischemia, severe bleeding, balloon leakage, and death)
occurred in 2.6% of the patients, and PVD was an indepen-
dent predictor of balloon-related complications.23
In our study, 42 patients (19.5%) had PVD. IABP-related
vascular complications occurred among 14.3% (vs 4% in
non-PVD patients; P ¼ .023), leading to an increased hos-
pital stay (21.2 vs 11.8 days in patients without PVD;
P ¼ .001) and decreased 10-year survival (Kaplan-Meier,
21.4%  6.3%). Moreover, Cox analysis showed PVD to
be associated with increased overall mortality and MACCE
(Table 5).
Study Limitations
First, ours was a retrospective observational cohort study,
and many of the identified factors could have been affected
by selection bias. The number of bypass grafts was protec-
tive. The greatest difference in survival was observed be-
tween the use of 1 and 2 grafts (Figure 3). The observed
difference could have resulted from other factors such as
the quality of the distal vessels or ‘‘graft-ability.’’ The
same argument applies to the observed benefit of BITA
grafting and the observed harm of OPCAB.
Second, we used an old registry (1996 to 2001) that had
been coded according to EuroSCORE I. Our data were not
coded using a method that enabled calculation of Euro-
SCORE II or the Society of Thoracic Surgeons score. Our
study compared the patients’ observed morality with the lo-
gistic EuroSCORE I calculated mortality, which probably
overestimated the mortality. With more modern calculators,
the difference between the observed and calculated morality
might not be as large, and, in some subgroups, the observed
morality might even be greater than the predicted morality.
Third, owing to the retrospective nature of the present
study, several potential advantages of preoperative IABP
insertion could not be addressed without comparing our pa-
tients to similar high-risk patients who were not supported
preoperatively with IABP (control group).
Finally, despite the use of multivariate methods, residual
confounders could have remained that were not included in
the statistical analysis.
CONCLUSIONS
Our study has described the early and long-term out-
comes of 215 consecutive preoperatively IABP-supported
CABG patients treated during a 6-year period. The actual
early postoperative mortality observed in each of the
IABP subgroups was remarkably lower than the logistic
EuroSCORE calculated mortality. These good early postop-
erative outcomes might have been related to the preopera-
tive insertion of an IABP. In patients supported
preoperatively with an IABP, better early and long-term re-
sults were strongly related to a younger age, shorter CPB
time, and greater number of bypass grafts. We do not
recommend avoiding the use of CPB (OPCAB) owing togery c November 2014
Hemo et al Acquired Cardiovascular Disease
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Dthe significant decrease in overall survival and the increased
occurrence of MACE and MACCE in our OPCAB patients.
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